New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are ...

Most people with asthma and other lung diseases have no idea that commonly prescribed inhalers are helping make the planet warmer. Each puff has about the same climate impact as driving a gas-powered ...

In a bid to improve the pharma sector’s drive to cut down greenhouse emissions, several companies are advancing dry powder inhalers (DPIs) for respiratory conditions that are more eco-friendly than ...

Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in one healthcare system formulary led to increased healthcare utilization, a ...

Generic prescribing is officially encouraged in the UK.1 Concerns have been raised that there is a potential for patients to be dispensed an unfamiliar device in which they have received no training,2 ...

Please provide your email address to receive an email when new articles are posted on . “Many health care systems are discussing a transition to dry-powder inhalers that have a lower carbon footprint ...

The divided solid materials have a significant share in the products produced or employed in the pharmaceutical industries (such as active pharmaceutical ingredient (API), excipients, additives, and ...

Inhaled medications are the mainstay of pharmacological treatment for people with chronic obstructive pulmonary disease and asthma. This second article in a two-part series describes the procedure for ...

Dry Powder Inhalers (DPIs) are employed to supply a safe dose of Active Pharmaceutical Ingredient (API) to the deep lung. Image Credit: Freeman Technology An excipient transports the delicate ...

Delivering dry powders to the lungs and to the nasal cavity is gaining popularity in the pharmaceutical industry as both targets provide a large surface area for absorption, deliver drugs without ...

LEXINGTON, Mass.--Pulmatrix, a biotechnology company developing breakthrough therapies for respiratory diseases, today announced that its iSPERSE™ inhaled drug delivery platform demonstrated the ...

The dry powder inhaler market is projected to be worth USD 20.83 billion in 2024. The market is likely to reach USD 29.95 billion by 2034. The Industry is expected to surge at a CAGR of 3.70% from ...